China Duloxetine Market Investigation Report 2009-2018 adds report “Investigation Report on China Duloxetine Market, 2009-2018” to its store.

Depression is a common mood disorder that belongs to highincidence mental diseases worldwide. Its main clinical features are a state of low mood and aversion to activity, and sometimes even suicidal thoughts or behaviors.

According to statistics from World Health Organization (WHO), depression is one of the most disabling diseases in the world today with over 0.3 billion sufferers worldwide. Because there are 10 to 20 million patients with suicidal thoughts every year in the world, it is said that 21 century is a “Century of Depression”. China is going through social transformation, which is also a period with high incidence of psychological problems. Statistics shows that there are more than 30 million depression patients now in China, of which over 80% have never been treated because of low income or other issues. Depression patients take up 50% to 70% of suicides and attempted suicides in China. Obviously, depression has become a major social problem in China.

Since Eli Lilly and Company first launched duloxetine (brand name “Cymbalta”) in August 2004, its sales revenue has been continually increasing, which nearly reached USD 5 billion in 2012.

Inquire for a discount on this report @ .

The success of duloxetine sales also comes from its persistent exploration and study into indications. It is approved to treat adult depression by FDA and EU in August and September 2004 respectively. In September 2004 FDA approved its treatment for new important indications of diabetic peripheral neuropathic pain, making it the first drug approved for these diseases. In August 2004 duloxetine was also approved to cure women patients who lack effective treatment of moderate  severe stress urinary incontinence symptoms. Duloxetine was also authorized to treat fibromyalgia in June 2008 and chronic musculoskeletal pain in November 2010 by FDA. It is this constant innovation that makes duloxetine produced by Eli Lilly and Company best selling antidepressant worldwide. Before patent of duloxetine expired at the end of 2013, almost all famous general drug manufacturers planed to seize this great opportunity. In recent years, some pharmaceutical companies have earned provisional approvals issued by FDA.

Many manufacturers did not report the production of raw materials and preparation until 2005. However, only Shanghai Zhongxi Pharmaceutical Co., Ltd. successfully produced generic drug before duloxetine was under administrative protection, and was given the production approval of entericcoated capsules and entericcoated tablets. In present Chinese market, only Eli Lilly and Company and Shanghai Zhongxi Pharmaceutical Co., Ltd. are approved to sell duloxetine products. Yet in July 2013, some other manufacturers received drug registration approval of duloxetine APIs and entericcoated tablet issued by FDA, whose products are expected to go on the market in 2014.

Complete report is available @ .

In China, antidepressants are still niche products. According to CRI’s investigation, market size of antidepressant in China was less than CNY 4 billion in 2013. Main cause of current situation is society’s lack of understanding of depression, which discourages patients from psychiatric treatment because of the prejudice. Another reason is people’s lack of knowledge about depression. When depression occurs, people may consider it as emotional problems and miss the best time for medical treatment, leading to further deterioration. Low market demand leads to slow development of antidepressants by drug manufacturers. However, as Chinese society develops and people’s living standard improves, Chinese people would require spiritual life of higher quality, which bestows antidepressant market a promising future. Market size of duloxetine therefore will soon increase rapidly.

Through this report, the readers can acquire the following information:

  • Incidence of Depression in China
  • Market Share of Major Duloxetine Manufacturers in Sample Hospitals in China
  • Sales price of Duloxetine in Hospital Market in China
  • Production Status of Duloxetine Generic Drug in China
  • Major Duloxetine Manufacturers in China
  • Share of Duloxetine in Different Dosage Forms in China Hospital Market
  • Prospect of China Duloxetine Market

The author recommends the report to the following:

  • Antidepressant APIs and Finished Product Manufacturers
  • Medical Institutions
  • Investors /Research Agencies Focusing on China Antidepressant Market

Purchase a copy of this report @ .

Browse Hypertension Drugs Industry Reports @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter :!/RnRMR

Facebook :

Google Plus :